These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24780091)

  • 21. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
    Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial.
    Yorgancıoğlu A; Öner Erkekol F; Mungan D; Erdinç M; Gemicioğlu B; Özşeker ZF; Bayrak Değirmenci P; Naycı S; Çilli A; Erdenen F; Kırmaz C; Ediger D; Yalçın AD; Büyüköztürk S; Öztürk S; Güleç M; Işık SR; Kalyoncu AF; Göksel Ö; Aydın Ö; Havlucu Y; Baloğlu Ar İ; Erdoğdu A
    Int Arch Allergy Immunol; 2018; 176(3-4):225-233. PubMed ID: 29772578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.
    Folqué MM; Lozano J; Riggioni C; Piquer M; Álvaro M; Machinena A; Giner MT; Domínguez O; Jiménez-Feijoo RM; Dias da Costa M; Plaza AM
    Allergol Immunopathol (Madr); 2019; 47(4):336-341. PubMed ID: 30509559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
    Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
    Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
    Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
    Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
    Chen HC; Huang CD; Chang E; Kuo HP
    BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
    Weheba IM; Abdelsayed AM; Arnaout RK; Zeitouni MO; Mobaireek KF; AlHarthi TB; Mobeireek AF
    Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases.
    Aydın Ö; Sözener ZÇ; Soyyiğit Ş; Kendirlinan R; Gençtürk Z; Mısırlıgil Z; Mungan D; Sin BA; Demirel YS; Çelik GE; Bavbek S
    Allergy Asthma Proc; 2015; 36(6):493-500. PubMed ID: 26534756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.